We are live on ! Find out more
AC

Aisling Capital Portfolio holdings

AUM $45.3M
1-Year Est. Return 15.24%
This Fund
S&P 500
This Quarter Est. Return
+49.72%
1 Year Est. Return
-15.24%
3 Year Est. Return
+386.13%
5 Year Est. Return
+981.36%
10 Year Est. Return
–
AUM
$584M
AUM Growth
+$34.6M
Cap. Flow
-$98.3M
Cap. Flow %
-16.84%
Top 10 Hldgs %
97.28%
Holding
17
New
–
Increased
1
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
ASXC
Asensus Surgical, Inc.
ASXC
+$1.46M

Top Sells

Rank Stock Value
1
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$90M
2
TTOO
T2 Biosystems, Inc
TTOO
+$5.23M
3
XENT
Intersect ENT, Inc
XENT
+$3.86M

Sector Composition

Rank Sector Weight
1 Healthcare 79.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
$336M 57.53%
4,188,920
– –
AIMT
2
DELISTED
Aimmune Therapeutics
AIMT
$61.5M 10.53%
2,990,000
– –
VRAY
3
DELISTED
ViewRay, Inc.
VRAY
$48.4M 8.29%
7,480,887
– –
ESPR
4
DELISTED
Esperion Therapeutics
ESPR
$38.7M 6.64%
837,125
– –
ARAV
5
DELISTED
Aravive, Inc. Common Stock
ARAV
$35.3M 6.05%
337,411
– –
ADMA icon
6
ADMA Biologics
ADMA
$2.03B
$13.3M 2.29%
3,608,171
– –
PRTK
7
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$11.6M 1.99%
482,680
– –
SYRS
8
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$8.18M 1.4%
50,857
– –
CDTX
9
DELISTED
Cidara Therapeutics
CDTX
$7.66M 1.31%
51,057
– –
ASXC
10
DELISTED
Asensus Surgical, Inc.
ASXC
$7.34M 1.26%
795,063
+153,846
+24% +$1.46M
AGRX
11
DELISTED
Agile Therapeutics
AGRX
$6.77M 1.16%
902
– –
TTOO
12
DELISTED
T2 Biosystems, Inc
TTOO
$4.89M 0.84%
305
-261
-46% -$5.23M
CMRX
13
DELISTED
Chimerix, Inc.
CMRX
$2.58M 0.44%
472,943
– –
PTX
14
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$844K 0.14%
210,000
– –
XENT
15
DELISTED
Intersect ENT, Inc
XENT
– –
-225,000
Closed -$3.86M
ZLTQ
16
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$0 ﹤0.01%
11,985
-1,597,742
-99% -$90M

Similar funds

SCPM
Sagard Capital Partners Management New York $46.7M AUM 23.43% 1-Year Est. Return
ZIM
ZPR Investment Management Orange City, Florida $46.8M AUM 2.45% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return
INL
IPC/NYCG LLC New York $43.3M AUM 61.41% 1-Year Est. Return
CP
Clover Partners Dallas, Texas $43.1M AUM 4.09% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
JCM
Julex Capital Management Wellesley, Massachusetts $42.4M AUM 9.78% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return

Aisling Capital's Q2 2017 Portfolio in Review

As of Q2 2017, Aisling Capital held 17 positions worth $584M, up 6.3% from $549M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Aisling Capital withdrew a net $98.3M in Q2 2017, closing 1 position and reducing 2 holdings. Its most notable exit was Intersect ENT, Inc, an estimated $3.86M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 72% a quarter earlier.

Against the trend, Aisling Capital added an estimated $1.46M to Asensus Surgical, Inc..

  • Aisling Capital added most to Asensus Surgical, Inc. in Q2 2017, an estimated $1.46M increase.
  • Aisling Capital's biggest Q2 2017 reduction was ZELTIQ Aesthetics, Inc., cutting an estimated $90M.
  • Aisling Capital fully exited Intersect ENT, Inc in Q2 2017, selling an estimated $3.86M.
  • Aisling Capital's ten largest holdings make up 97% of its $584M portfolio in Q2 2017.
  • Aisling Capital opened 0 new positions and closed 1 in Q2 2017.
  • Aisling Capital's portfolio value rose 6.3% quarter-over-quarter to $584M.

Based on Aisling Capital's 13F filing for Q2 2017, filed 14 Aug 2017.